PMV Pharmaceuticals, Inc. 8-K

What Happened

• PMV Pharmaceuticals, Inc. held its virtual 2026 Annual Meeting of Stockholders on June 4, 2026 and filed an 8-K reporting the voting results.
• Two Class III directors were elected to serve until the 2029 annual meeting: David H. Mack, Ph.D., and Laurie Stelzer. The company also reported the non-binding advisory vote on executive compensation (say-on-pay) and ratification of Ernst & Young LLP as the independent auditor for fiscal 2026.

Key Details

• Director election results:
  • David H. Mack, Ph.D.: For 15,693,907; Withheld 6,248,461; Broker non-vote 6,975,412.
  • Laurie Stelzer: For 11,261,111; Withheld 10,681,257; Broker non-vote 6,975,412.
• Say-on-pay (non-binding advisory vote on named executive officer compensation): For 15,015,578; Against 6,468,718; Abstain 458,072; Broker non-vote 6,975,412. The company conducts annual advisory votes on pay per a 2022 stockholder-approved policy; the next frequency vote is expected in 2028.
• Auditor ratification: Ernst & Young LLP was ratified as PMV’s independent registered public accounting firm for the fiscal year ending December 31, 2026 — For 28,379,108; Against 536,302; Abstain 2,370.
• The Proxy Statement referenced was filed April 22, 2026.

Why It Matters

• Election outcomes determine board composition and governance through 2029; close voting margins (notably for Laurie Stelzer and the say-on-pay vote) show meaningful shareholder dissent that investors should monitor for potential governance or compensation concerns.
• Ratification of Ernst & Young LLP provides continuity for financial reporting and audit oversight for fiscal 2026.
• These results are factual, non-financial corporate governance updates that can affect investor confidence and future engagement on strategy, compensation and oversight.